| Triple-negative breast cancer: clinical features and patterns of recurrence R Dent, M Trudeau, KI Pritchard, WM Hanna, HK Kahn, CA Sawka, ... Clinical cancer research 13 (15), 4429-4434, 2007 | 6277 | 2007 |
| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 2390 | 2020 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of oncology 32 (12), 1475-1495, 2021 | 912 | 2021 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 873 | 2022 |
| Pattern of metastatic spread in triple-negative breast cancer R Dent, WM Hanna, M Trudeau, E Rawlinson, P Sun, SA Narod Breast cancer research and treatment 115, 423-428, 2009 | 790 | 2009 |
| Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy T Byrski, J Gronwald, T Huzarski, E Grzybowska, M Budryk, M Stawicka, ... Journal of Clinical Oncology 28 (3), 375-379, 2010 | 732 | 2010 |
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design F Kassam, K Enright, R Dent, G Dranitsaris, J Myers, C Flynn, M Fralick, ... Clinical breast cancer 9 (1), 29-33, 2009 | 567 | 2009 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 527 | 2017 |
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 522 | 2013 |
| Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients T Byrski, T Huzarski, R Dent, J Gronwald, D Zuziak, C Cybulski, J Kladny, ... Breast cancer research and treatment 115, 359-363, 2009 | 465 | 2009 |
| Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... The Lancet Oncology 22 (4), 499-511, 2021 | 383 | 2021 |
| Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 … P Schmid, R Salgado, YH Park, E Muñoz-Couselo, SB Kim, J Sohn, SA Im, ... Annals of Oncology 31 (5), 569-581, 2020 | 359 | 2020 |
| Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients T Byrski, T Huzarski, R Dent, E Marczyk, M Jasiówka, J Gronwald, ... Breast cancer research and treatment 147, 401-405, 2014 | 347 | 2014 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 339 | 2020 |
| ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) S Paluch-Shimon, O Pagani, AH Partridge, O Abulkhair, MJ Cardoso, ... The Breast 35, 203-217, 2017 | 256 | 2017 |
| Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study YT Cheung, T Ng, M Shwe, HK Ho, KM Foo, MT Cham, JA Lee, G Fan, ... Annals of Oncology 26 (7), 1446-1451, 2015 | 250 | 2015 |
| Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer T Byrski, R Dent, P Blecharz, M Foszczynska-Kloda, J Gronwald, ... Breast cancer research 14, 1-8, 2012 | 246 | 2012 |
| Targeting triple-negative breast cancer: optimising therapeutic outcomes K Gelmon, R Dent, JR Mackey, K Laing, D McLeod, S Verma Annals of oncology 23 (9), 2223-2234, 2012 | 232 | 2012 |
| Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer RA Dent, GJ Lindeman, M Clemons, H Wildiers, A Chan, NJ McCarthy, ... Breast cancer research 15, 1-8, 2013 | 228 | 2013 |
| Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ... The pharmacogenomics journal 15 (1), 84-94, 2015 | 220 | 2015 |
